title: [Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?].
abstract: It is now well accepted that a chronic, low-grade inflammation is observed in abdominal obesity, insulin resistance and type 2 diabetes mellitus, and that pro-inflammatory cytokines and oxidative stress play a role in the pathogenesis of type 2 diabetes. These new findings raise the question of whether antiinflammatory strategies may have a place in the prevention and treatment of type 2 diabetes. This review article describes the results obtained in studies on patients with metabolic syndrome or type 2 diabetes aiming to test the metabolic effect of anti-inflammatory (salicylates, antagonists of interleukine-1, antagonists of tumor necrosis factor-alpha) and anti-oxydants (succinobucol) drugs.
authors.affiliation: Service de diabétologie, nutrition et maladies métaboliques, Département de médecine, CHU Sart-Tilman, Université de Liège, 4000 Liège, Belgique. nathalie.esser@student.ulg.ac.be
authors.forename: N
authors.initials: N
authors.lastname: Esser
authors.forename: N
authors.initials: N
authors.lastname: Paquot
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents